Bioverativ and Bicycle Therapeutics announce new research partnership

Bioverativ has announced a new strategic research collaboration with the biotechnology company Bicycle Therapeutics.

The alliance will focus on the discovery, development and commercialisation of innovative therapies for haemophilia and sickle cell disease, leveraging the proprietary Bicycle bicyclic peptide product platform.

Bicycle therapies combine attributes of antibodies, small molecules and peptides within a single molecule, enabling high selectivity and affinity while simultaneously offering the capability to penetrate and bind to targets of interest within the body.

Under the terms of the collaboration, Bicycle Therapeutics will be responsible for leading initial discovery activities, from lead optimisation to candidate selection, for two separate programmes.

Bioverativ, meanwhile, will lead preclinical and clinical development, as well as subsequent marketing and commercialisation, and will reimburse Bicycle for internal and external programme-related costs.

Dr Tim Harris, executive vice-president of research and development at Bioverativ, said: "This collaboration offers a unique opportunity to identify an entirely new therapeutic modality that may lead to meaningful new treatments and outcomes for people living with haemophilia and sickle cell disease."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.